PL3423440T3 - Pochodna 5-metylo-6-fenylo-4,5-dihydro-2h-pirydazyn-3-onu do leczenia nowotworów mózgu - Google Patents
Pochodna 5-metylo-6-fenylo-4,5-dihydro-2h-pirydazyn-3-onu do leczenia nowotworów mózguInfo
- Publication number
- PL3423440T3 PL3423440T3 PL17711366T PL17711366T PL3423440T3 PL 3423440 T3 PL3423440 T3 PL 3423440T3 PL 17711366 T PL17711366 T PL 17711366T PL 17711366 T PL17711366 T PL 17711366T PL 3423440 T3 PL3423440 T3 PL 3423440T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridazin
- dihydro
- phenyl
- derivative
- methyl
- Prior art date
Links
- GVASAZMJZKWWEA-UHFFFAOYSA-N 4-methyl-3-phenyl-4,5-dihydro-1h-pyridazin-6-one Chemical class CC1CC(=O)NN=C1C1=CC=CC=C1 GVASAZMJZKWWEA-UHFFFAOYSA-N 0.000 title 1
- 208000003174 Brain Neoplasms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016042535 | 2016-03-04 | ||
| PCT/JP2017/008246 WO2017150654A1 (en) | 2016-03-04 | 2017-03-02 | 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative |
| EP17711366.9A EP3423440B9 (en) | 2016-03-04 | 2017-03-02 | 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative for the treatment of brain tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3423440T3 true PL3423440T3 (pl) | 2021-07-26 |
Family
ID=58347859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17711366T PL3423440T3 (pl) | 2016-03-04 | 2017-03-02 | Pochodna 5-metylo-6-fenylo-4,5-dihydro-2h-pirydazyn-3-onu do leczenia nowotworów mózgu |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10611731B2 (pl) |
| EP (1) | EP3423440B9 (pl) |
| JP (1) | JP6596595B2 (pl) |
| KR (1) | KR102350772B1 (pl) |
| CN (1) | CN108779076B (pl) |
| AU (2) | AU2017226674B2 (pl) |
| CY (1) | CY1123927T1 (pl) |
| DK (1) | DK3423440T3 (pl) |
| EA (1) | EA036423B1 (pl) |
| ES (1) | ES2862177T3 (pl) |
| HR (1) | HRP20210395T1 (pl) |
| HU (1) | HUE053358T2 (pl) |
| IL (1) | IL261225B (pl) |
| LT (1) | LT3423440T (pl) |
| MX (1) | MX377854B (pl) |
| MY (1) | MY196801A (pl) |
| NZ (1) | NZ745688A (pl) |
| PH (1) | PH12018501873B1 (pl) |
| PL (1) | PL3423440T3 (pl) |
| PT (1) | PT3423440T (pl) |
| RS (1) | RS61593B1 (pl) |
| SA (1) | SA518392275B1 (pl) |
| SG (1) | SG11201807146SA (pl) |
| SI (1) | SI3423440T1 (pl) |
| SM (1) | SMT202100138T1 (pl) |
| TW (1) | TWI731041B (pl) |
| WO (1) | WO2017150654A1 (pl) |
| ZA (1) | ZA201805791B (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7104588B2 (ja) * | 2017-09-01 | 2022-07-21 | 大塚製薬株式会社 | ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤 |
| AR117929A1 (es) * | 2019-02-01 | 2021-09-01 | Bayer Ag | Compuestos de 1,2,4-triazin-3(2h)-ona |
| KR20260006625A (ko) | 2023-05-08 | 2026-01-13 | 오츠카 세이야쿠 가부시키가이샤 | 거대핵세포 분화 및 성숙의 억제제 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63145272A (ja) | 1986-12-09 | 1988-06-17 | Morishita Seiyaku Kk | ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体 |
| US5100892A (en) * | 1990-11-13 | 1992-03-31 | Glaxo Inc. | Dihydropyridine vasodilator agents |
| US5563143A (en) * | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| CA2205757C (en) * | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| CA2588949A1 (en) * | 2004-11-30 | 2006-06-08 | Artesian Therapeutics, Inc. | Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
| CA2692248A1 (en) | 2007-06-19 | 2008-12-24 | Kyorin Pharmaceutical Co., Ltd. | Pyridazinone derivative and pde inhibitor containing the same as active ingredient |
| CN101537006B (zh) * | 2008-03-18 | 2012-06-06 | 中国科学院上海药物研究所 | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 |
| JP6511430B2 (ja) * | 2013-03-11 | 2019-05-15 | ザ・ブロード・インスティテュート・インコーポレイテッド | がんの治療のための化合物および組成物 |
-
2017
- 2017-03-02 SI SI201730668T patent/SI3423440T1/sl unknown
- 2017-03-02 ES ES17711366T patent/ES2862177T3/es active Active
- 2017-03-02 MX MX2018010535A patent/MX377854B/es unknown
- 2017-03-02 PT PT177113669T patent/PT3423440T/pt unknown
- 2017-03-02 TW TW106106813A patent/TWI731041B/zh active
- 2017-03-02 EP EP17711366.9A patent/EP3423440B9/en active Active
- 2017-03-02 LT LTEP17711366.9T patent/LT3423440T/lt unknown
- 2017-03-02 HU HUE17711366A patent/HUE053358T2/hu unknown
- 2017-03-02 WO PCT/JP2017/008246 patent/WO2017150654A1/en not_active Ceased
- 2017-03-02 CN CN201780013870.4A patent/CN108779076B/zh active Active
- 2017-03-02 AU AU2017226674A patent/AU2017226674B2/en active Active
- 2017-03-02 NZ NZ745688A patent/NZ745688A/en unknown
- 2017-03-02 US US16/081,260 patent/US10611731B2/en active Active
- 2017-03-02 PL PL17711366T patent/PL3423440T3/pl unknown
- 2017-03-02 SG SG11201807146SA patent/SG11201807146SA/en unknown
- 2017-03-02 KR KR1020187028010A patent/KR102350772B1/ko active Active
- 2017-03-02 EA EA201891987A patent/EA036423B1/ru not_active IP Right Cessation
- 2017-03-02 SM SM20210138T patent/SMT202100138T1/it unknown
- 2017-03-02 JP JP2018544577A patent/JP6596595B2/ja active Active
- 2017-03-02 PH PH1/2018/501873A patent/PH12018501873B1/en unknown
- 2017-03-02 RS RS20210193A patent/RS61593B1/sr unknown
- 2017-03-02 DK DK17711366.9T patent/DK3423440T3/da active
- 2017-03-02 MY MYPI2018703021A patent/MY196801A/en unknown
- 2017-03-02 HR HRP20210395TT patent/HRP20210395T1/hr unknown
-
2018
- 2018-08-19 IL IL261225A patent/IL261225B/en unknown
- 2018-08-26 SA SA518392275A patent/SA518392275B1/ar unknown
- 2018-08-29 ZA ZA2018/05791A patent/ZA201805791B/en unknown
-
2020
- 2020-02-12 US US16/788,894 patent/US20200181092A1/en not_active Abandoned
-
2021
- 2021-02-22 AU AU2021201135A patent/AU2021201135B2/en active Active
- 2021-02-23 US US17/182,549 patent/US20210171472A1/en not_active Abandoned
- 2021-02-24 CY CY20211100155T patent/CY1123927T1/el unknown
-
2024
- 2024-08-08 US US18/798,284 patent/US20240400520A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285151A (en) | Methods of treating fgf21-associated disorders | |
| IL269026A (en) | Methods of treating tumor | |
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| IL269371A (en) | Treatment methods | |
| IL255261A0 (en) | Methods for treating cancer | |
| IL284875A (en) | Lasofoxifene treatment of breast cancer | |
| LT3468965T (lt) | 1-tetrahidropiranilkarbonil-2,3-dihidro-1h-indolo junginiai vėžio gydymui | |
| HUE059694T2 (hu) | Készítmény rák kezelésére | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| HUE038541T2 (hu) | Rák kezelési módszerek | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| LT3353177T (lt) | Tricikliniai heterociklai, skirti vėžio gydymui | |
| IL265751B (en) | Immunogenic compounds for cancer therapy | |
| PL3439663T3 (pl) | Sposoby leczenia nowotworów wieku dziecięcego | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| DK3576740T3 (da) | Cancerbehandling | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| EP3493821A4 (en) | METHOD OF TREATING THE RESPIRATORY TRACT | |
| KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 | |
| IL262801A (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| SI3448382T1 (sl) | Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo | |
| IL271307A (en) | Methods of treating brain tumors using combination therapy |